Jubilant Organosys partners with UAB and Southern Research on drug discovery

Jubilant Organosys has formed an drug discovery alliance with the University of Alabama at Birmingham (UAB) and Southern Research Institute to carry out joint research in oncology, metabolic diseases and infectious diseases.

Jubilant Organosys has signed a memorandum of understanding with University of Alabama at Birmingham (UAB) and Southern Research Institute for a joint venture focusing on leveraging their collective innovation and enabling technologies in the areas of oncology, metabolic disease and infectious Diseases.

“UAB has tremendous strength in research that identifies the targets – usually proteins – that contribute to the disease process, whether it is cancer or diabetes, which develop when our bodies malfunction, or a virus or bacterial infection that invades from outside,” said Richard B. Marchase, UAB Vice President for Research and Economic Development.

Meanwhile, Southern Research and Jubilant have the expertise, scientific workforce, and the equipment to take those findings and move them rapidly through the drug discovery and testing phases that lead to new commercially viable products.

Southern Research has earned worldwide acclaim for its success translating basic research into drugs that can be used to treat human illness, having discovered and helped move seven FDA-approved cancer drugs to market, with five more drugs in late-stage preclinical and early clinical studies.

Selecting the most promising biological targets discovered by biomedical researchers at UAB,Southern Research and Jubilant; developing new drugs around these targets t